About this Research Topic
Cell cycle inhibitors have emerged as one of the most powerful targeted therapies beyond endocrine therapy in hormone receptor positive breast cancer. While gathering clinical information on efficacy and tolerance of these agents, further development is occurring on other disease settings and cancer types. New treatment combinations and dose schedules have been explored. Coupled with the emergence of complex molecular data identifying key molecular pathways in multiple cancer types current data supports a radically different approach to development, testing and validation of molecularly targeted therapeutics in women's cancers. We would like authors to propose new perspectives in basic, translational and clinical trials research which will accelerate the delivery of targeted therapeutics. In this Research Topic, we welcome review articles, perspectives, research articles dealing with targeted therapeutics directed against cell cycle checkpoints in women’s cancer.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.